Publications
Detailed Information
KEYNOTE-859: a Phase III study of pembrolizumab plus chemotherapy in gastric/gastroesophageal junction adenocarcinoma
DC Field | Value | Language |
---|---|---|
dc.contributor.author | Tabernero, Josep | - |
dc.contributor.author | Bang, Yung-Jue | - |
dc.contributor.author | Van Cutsem, Eric | - |
dc.contributor.author | Fuchs, Charles S. | - |
dc.contributor.author | Janjigian, Yelena Yuriy | - |
dc.contributor.author | Bhagia, Pooja | - |
dc.contributor.author | Li, Kan | - |
dc.contributor.author | Adelberg, David | - |
dc.contributor.author | Qin, Shu Kui | - |
dc.date.accessioned | 2022-04-18T09:24:21Z | - |
dc.date.available | 2022-04-18T09:24:21Z | - |
dc.date.created | 2021-08-24 | - |
dc.date.created | 2021-08-24 | - |
dc.date.created | 2021-08-24 | - |
dc.date.created | 2021-08-24 | - |
dc.date.created | 2021-08-24 | - |
dc.date.created | 2021-08-24 | - |
dc.date.created | 2021-08-24 | - |
dc.date.created | 2021-08-24 | - |
dc.date.issued | 2021-03 | - |
dc.identifier.citation | Future Oncology, Vol.17 No.22, pp.2847-2855 | - |
dc.identifier.issn | 1479-6694 | - |
dc.identifier.other | 140162 | - |
dc.identifier.uri | https://hdl.handle.net/10371/178100 | - |
dc.description.abstract | Current guidelines recommend two-drug cytotoxic chemotherapy with a fluoropyrimidine (fluorouracil or capecitabine) and a platinum-based agent (oxaliplatin or cisplatin) as first-line treatment for advanced gastric cancer. Pembrolizumab monotherapy has demonstrated durable antitumor activity in patients with advanced programmed death ligand 1-positive (combined positive score >= 1) gastric/gastroesophageal junction adenocarcinoma. Accumulating evidence indicates that combining pembrolizumab with standard-of-care chemotherapy for the treatment of advanced or metastatic cancer improves clinical outcomes. We describe the rationale for and the design of the randomized, double-blind, placebo-controlled, Phase III KEYNOTE-859 study, which is investigating pembrolizumab in combination with chemotherapy as first-line treatment for patients with human epidermal growth factor receptor 2-negative advanced unresectable or metastatic gastric/gastroesophageal junction adenocarcinoma. The planned sample size is 1542 patients, and the primary end point is overall survival. | - |
dc.language | 영어 | - |
dc.publisher | Future Medicine Ltd. | - |
dc.title | KEYNOTE-859: a Phase III study of pembrolizumab plus chemotherapy in gastric/gastroesophageal junction adenocarcinoma | - |
dc.type | Article | - |
dc.contributor.AlternativeAuthor | 방영주 | - |
dc.identifier.doi | 10.2217/fon-2021-0176 | - |
dc.citation.journaltitle | Future Oncology | - |
dc.identifier.wosid | 000649323900001 | - |
dc.identifier.scopusid | 2-s2.0-85111039373 | - |
dc.citation.endpage | 2855 | - |
dc.citation.number | 22 | - |
dc.citation.startpage | 2847 | - |
dc.citation.volume | 17 | - |
dc.identifier.sci | 000649323900001 | - |
dc.description.isOpenAccess | Y | - |
dc.contributor.affiliatedAuthor | Bang, Yung-Jue | - |
dc.type.docType | Article | - |
dc.description.journalClass | 1 | - |
dc.subject.keywordPlus | OPEN-LABEL | - |
dc.subject.keywordPlus | CANCER | - |
dc.subject.keywordPlus | NIVOLUMAB | - |
dc.subject.keywordPlus | RECURRENT | - |
dc.subject.keywordAuthor | adenocarcinoma | - |
dc.subject.keywordAuthor | chemotherapy | - |
dc.subject.keywordAuthor | first-line therapy | - |
dc.subject.keywordAuthor | gastric cancer | - |
dc.subject.keywordAuthor | gastroesophageal junction cancer | - |
dc.subject.keywordAuthor | HER2-negative | - |
dc.subject.keywordAuthor | immunotherapy | - |
dc.subject.keywordAuthor | pembrolizumab | - |
- Appears in Collections:
- Files in This Item:
- There are no files associated with this item.
Item View & Download Count
Items in S-Space are protected by copyright, with all rights reserved, unless otherwise indicated.